Amzeeq topical foam 4% will soon be available (January 13, 2020) by prescription for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older.
As there exist limited conclusions about blue-light therapy for acne, clinicians and patients should consider the balance between benefits and adverse events, as well as costs, when considering this therapy.
Racial and sex differences in response to once-daily tretinoin were observed in patients with acne, with efficacy greatest in white women.
Results from a novel study suggest that there is no specific Cutibacterium acnes phylotype associated with acne fulminans, raising the possibility that the mechanism involved in acne fulminans could be more related to abnormal activation of the cutaneous innate immunity.
The FDA has approved Arazlo (tazarotene; Ortho Dermatologics) Lotion 0.045% for the treatment of acne vulgaris in patients aged 9 years and older.
Results suggest that although silymarin monotherapy is not as effective as doxycycline for the treatment of acne vulgaris, it can be a therapeutic option.
The antimicrobial activity of nonantibiotic acne agents may provide protection against a background of increased drug-resistant bacteria.
Photodynamic therapy was shown to have beneficial effects on inflammatory acne vulgaris and can be widely used to treat inflammatory acne vulgaris in clinic.
Data demonstrate the positive effect of weekly adalimumab treatment on incidence of hidradenitis suppurativa disease flare, time to flare, and duration of flare.
A study reveals the potential role of topical ketoconazole monotherapy as a viable acne treatment without concern for antibiotic resistance.